Information leaflets for patients with hepatitis C receiving treatment with triple therapy
- Inés Yeste-Gómez,
- Carmen Guadalupe Rodríguez-González,
- Álvaro Giménez-Manzorro,
- Arantza Ais-Larisgoitia,
- María Sanjurjo-Saez
- Correspondence to Dr Inés Yeste-Gómez, Department of Pharmacy, Hospital General Universitario Gregorio Marañón, Calle Dr. Esquerdo 46, 28007 Madrid, Spain;
The NS3/4 protease inhibitors boceprevir and telaprevir in conjunction with peginterferon α and ribavirin (triple therapy) increase the rate of a sustained virological response in patients with genotype-1 chronic hepatitis C but, to achieve a successful result, good compliance is vital. As part of a pharmaceutical care programme, in the Outpatient Pharmacy we developed information leaflets to help patients understand the objectives of triple therapy, to be aware and prevent the possible side effects and to teach patients how to take the medicines.